Clinical Trial Search

Primary: Area Under the Concentration-time Curve for Serum Insulin From Time 0 to 60 Minutes (AUC0-60) — 11667.14; 23807.14; 10687.14; 27850.00 minutes*nanomolars (min*nM)…

Primary: AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity) — 10500; 12400; 12600; 17500 nmol*h/L

Primary: Intra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T]) — 14.04; 23.81; 40.51…

Primary: Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests — 0.0; 0.0; 0.0; 0.0 percentage of…

Primary: Limiting Toxicity — 1; 1; 3; 2 participants

Primary: Pharmacokinetics (PK) of Leucovorin — 6.43; 1.13 micromol x hour/L

Primary: Total Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞) — 2240; 3020; 3400 nmol*h/L

Primary: Safety of Single Ascending Doses of GGF2 Via an Assessment of the Toxicology Profile as Measured by Treatment Emergent Adverse Events (TEAEs) — 6; 4; 4; 2 participants

Primary: Number of Participants Without Defibrillation — 94; 97 participants

Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 5380; 4520; 2280 nmol*h/L

Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants

Primary: Scores on the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version — 13.6; 13.3; 8.3; 22.6 units on a scale

Primary: Quantitative Assessment of Neocortical SUVRs (Mean Standard Uptake Value Ratios) as a Measure of Florbetaben Uptake — 1.430; 1.726; 1.442; 1.738 SUVR — p=0.0001

Primary: Platelet - Leukocyte Aggregates — 29.2; 39.8; 26.2; 21.1 % leukocytes with platelets attached

Primary: Safety and Tolerability of Dalfampridine-ER 10mg in Subjects With Cerebral Palsy (CP) — 1; 2; 6; 9 participants